Could a diabetes pill protect eyesight in advanced dry AMD?
NCT ID NCT07174687
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with this condition will take the drug for 12 months. Researchers will measure changes in retinal damage and vision to see if the treatment is safe and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye imaging could reveal hidden clues to vision loss
- A new eye camera may spot stressed cells before vision loss begins
- One-Time gene injection aims to restore sight in rare childhood blindness
- Gene therapy injection aims to halt blinding eye disease
- Built-In eye scanner could give surgeons a live 3D view during operations
- Eye imaging showdown: which device measures macular damage best?